SG Americas Securities LLC Raises Stock Position in Stevanato Group S.p.A. (NYSE:STVN)

SG Americas Securities LLC lifted its stake in Stevanato Group S.p.A. (NYSE:STVN) by 18.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 15,546 shares of the company’s stock after buying an additional 2,389 shares during the period. SG Americas Securities LLC’s holdings in Stevanato Group were worth $339,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Hardy Reed LLC grew its position in shares of Stevanato Group by 8.2% during the third quarter. Hardy Reed LLC now owns 11,077 shares of the company’s stock worth $222,000 after acquiring an additional 840 shares during the last quarter. Lindenwold Advisors INC grew its position in Stevanato Group by 13.5% during the 3rd quarter. Lindenwold Advisors INC now owns 11,930 shares of the company’s stock worth $239,000 after purchasing an additional 1,415 shares during the last quarter. Captrust Financial Advisors raised its holdings in shares of Stevanato Group by 12.7% in the third quarter. Captrust Financial Advisors now owns 13,100 shares of the company’s stock valued at $262,000 after buying an additional 1,480 shares during the last quarter. Raymond James Trust N.A. boosted its stake in shares of Stevanato Group by 22.6% during the third quarter. Raymond James Trust N.A. now owns 12,556 shares of the company’s stock worth $251,000 after buying an additional 2,317 shares during the period. Finally, First Bank & Trust grew its holdings in shares of Stevanato Group by 29.1% during the third quarter. First Bank & Trust now owns 14,109 shares of the company’s stock worth $282,000 after buying an additional 3,182 shares during the last quarter.

Analyst Ratings Changes

A number of research firms have weighed in on STVN. Morgan Stanley reaffirmed an “equal weight” rating and set a $23.00 price objective (down from $24.00) on shares of Stevanato Group in a research report on Tuesday, December 3rd. Bank of America boosted their price objective on shares of Stevanato Group from $24.00 to $26.00 and gave the company a “buy” rating in a research note on Friday, December 13th. Finally, Wolfe Research initiated coverage on shares of Stevanato Group in a research note on Friday, December 13th. They set an “outperform” rating and a $28.00 price target on the stock. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, Stevanato Group has an average rating of “Moderate Buy” and a consensus target price of €28.60 ($29.48).

Stevanato Group Price Performance

Stevanato Group stock opened at €22.47 ($23.16) on Wednesday. The company has a market cap of $6.80 billion, a P/E ratio of 47.81, a price-to-earnings-growth ratio of 7.76 and a beta of 0.56. Stevanato Group S.p.A. has a one year low of €16.56 ($17.07) and a one year high of €34.73 ($35.80). The business has a fifty day moving average of €21.82 and a two-hundred day moving average of €20.51. The company has a debt-to-equity ratio of 0.22, a quick ratio of 1.21 and a current ratio of 1.81.

Stevanato Group (NYSE:STVN) last announced its quarterly earnings data on Tuesday, November 5th. The company reported €0.12 ($0.12) EPS for the quarter, missing the consensus estimate of €0.13 ($0.13) by (€0.01) (($0.01)). Stevanato Group had a net margin of 10.47% and a return on equity of 9.86%. The company had revenue of €277.90 million during the quarter, compared to analyst estimates of €274.36 million. During the same quarter last year, the business earned $0.16 EPS. The firm’s revenue for the quarter was up 2.4% on a year-over-year basis. As a group, analysts predict that Stevanato Group S.p.A. will post 0.5 earnings per share for the current fiscal year.

Stevanato Group Profile

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.